Acute liver injury associated with glucosamine dietary supplement
- PMID: 23239775
- PMCID: PMC4544092
- DOI: 10.1136/bcr-2012-007665
Acute liver injury associated with glucosamine dietary supplement
Abstract
A 55-year-old woman taking over-the-counter (OTC) glucosamine developed symptomatic hepatotoxicity. Several of her liver enzymes were elevated to 10 times the upper limit of normal. One week after discontinuing glucosamine, serum transaminases fell dramatically, with some returning to normal limits. Four weeks after glucosamine was discontinued, all her liver tests were normal. Rechallenge was not attempted. The potential causes of hepatocellular injury were evaluated. Glucosamine is a dietary supplement available in a wide variety of commercial preparations, primarily used for joint relief in osteoarthritis. Despite the extensive use of glucosamine supplements, significant elevations of transaminases are rare. The mechanism of hepatotoxicity in many OTC herbal preparations is unknown. It is vital for physicians to elicit a careful history of OTC medications and educate their patients on their potential adverse effects.
References
-
- Cibere J, Kopec JA, Thorne Aet al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004;51:738–45. - PubMed
-
- Clegg DO, Reda DJ, Harris CLet al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795–808. - PubMed
-
- McAlindon T, Formica M, LaValley M, et al. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004;117:643–9. - PubMed
-
- Towheed TE, Anastassiades T. Glucosamine therapy for osteoarthritis: an update. J Rheumatol 2007;34:1787–90. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical